- InnoCan (INNO) has expanded its CBD liposome platform technology to treat dogs
- Yissum Research Development Company will conduct the additional research for a C$100,000 fee
- A recent study indicated prolonged and plasma CBD concentrations in dogs for at least six weeks after a single administration
- InnoCan is a pharmaceutical tech company focused on the development of several drug delivery platforms containing CBD
- InnoCan (INNO) closed down by 1.39 per cent trading at $0.71 per share
InnoCan (INNO) has expanded its CBD liposome platform technology to treat dogs.
The company reflected the change in an amendment to the research and license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The agreement concerns the design, preparation, characterization and evaluation of CBD- loaded liposomes.
This patented technology may have a wide range of applications in epilepsy, pain relief, inflammation and central nervous system disorders.
Yissum will conduct the additional research for a C$100,000 fee.
In a recent study of InnoCan’s CBD-loaded liposome technology on dogs, CBD showed prolonged and plasma concentrations for at least six weeks after a single administration.
The company believes that successful results will lead to further research for other veterinary indications.
“We take pride in InnoCan’s agility to evolve and understand market trends,” said Iris Bincovich, CEO of InnoCan Pharma. “Our anticipated expansion to veterinary demonstrates how strong our scientific core is, allowing us to commercialize our IP in a variety of methods.”
InnoCan is a pharmaceutical tech company focused on the development of several drug delivery platforms containing CBD.
InnoCan (INNO) closed down by 1.39 per cent trading at $0.71 per share.